Fig. 1: ZNF154 promoter is hypermethylated in ESCC and correlates with poor prognosis. | Oncogene

Fig. 1: ZNF154 promoter is hypermethylated in ESCC and correlates with poor prognosis.

From: Targeted demethylation at ZNF154 promotor upregulates ZNF154 expression and inhibits the proliferation and migration of Esophageal Squamous Carcinoma cells

Fig. 1

A Methylation status of three CpG sites around CpG1 was analyzed by bisulfite sequencing in nine ESCC tissues, four NATs and two ESCC cell lines (Kyse-30 and Kyse-140). The three CpG sites are represented with the red circles. Open and filled circles represent unmethylated and methylated CpG sites respectively. Circles are partially filled according to the percentage of methylation. B The methylation ratios of white blood cells from healthy individuals (n = 16), NATs (n = 21) and ESCC tissues (n = 78). C The methylation ratios of normal people (n = 189) and ESCC patients (n = 75) from EECs are shown. D Receiver operating characteristic (ROC) curve of the MRs for distinguishing between normal people and ESCC patients. E The 5-year PFS of ESCC patients in the hypermethylated group (MR > 48%) and hypomethylated group (MR ≤ 48%). ***P < 0.001 2-tailed t test. Equation for MR: methylated droplets (MD)/(MD + unmethylated droplets (UMD)). NAT unpaired normal adjacent tissues, ESCC esophageal squamous carcinoma, MR methylation ratio, Se sensitivity, Sp specificity, Hyper hypermethylation, Hypo hypomethylation.

Back to article page